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ABSTRACT
Fewer than 50% of patients with high-risk neuroblastoma survive five years 
after diagnosis with current treatment protocols. Molecular targeted therapies are 
expected to improve survival. Although MDM2 has been validated as a promising 
target in preclinical models, no MDM2 inhibitors have yet entered clinical trials for 
neuroblastoma patients. Toxic side effects, poor bioavailability and low efficacy of the 
available MDM2 inhibitors that have entered phase I/II trials drive the development 
of novel MDM2 inhibitors with an improved risk-benefit profile. We investigated 
the effect of the novel MDM2 small molecular inhibitor, DS-3032b, on viability, 
proliferation, senescence, migration, cell cycle arrest and apoptosis in a panel of 
six neuroblastoma cell lines with different TP53 and MYCN genetic backgrounds, 
and assessed efficacy in a murine subcutaneous model for high-risk neuroblastoma. 
Re-analysis of existing expression data from 476 primary neuroblastomas showed 
that high-level MDM2 expression correlated with poor patient survival. DS-3032b 
treatment enhanced TP53 target gene expression and induced G1 cell cycle arrest, 
senescence and apoptosis. CRISPR-mediated MDM2 knockout in neuroblastoma 
cells mimicked DS-3032b treatment. TP53 signaling was selectively activated by DS-
3032b in neuroblastoma cells with wildtype TP53, regardless of the presence of MYCN 
amplification, but was significantly reduced by TP53 mutations or expression of a 
dominant-negative TP53 mutant. Oral DS-3032b administration inhibited xenograft 
tumor growth and prolonged mouse survival. Our in vitro and in vivo data demonstrate 
that DS-3032b reactivates TP53 signaling even in the presence of MYCN amplification 
in neuroblastoma cells, to reduce proliferative capacity and cause cytotoxicity.
INTRODUCTION
Inactivation of the crucial tumor suppressor, TP53, 
is a common event in tumorigenesis. TP53 activity can be 
functionally inhibited by TP53 mutation or deregulating 
components of the TP53 pathway. Next-generation 
sequencing in 32 cancer types established that TP53 
mutations occur in 35% of cancers [1]. However, in 
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neuroblastoma, the most common extracranial solid tumor 
of childhood, fewer than 2% of primary neuroblastomas 
[2–4] and 14% of relapsed neuroblastomas [5] harbor 
TP53 mutations. Deregulating MDM2 proto-oncogene 
expression is one effective mechanism to impede TP53 
activity. MDM2-TP53 binding is known to inhibit 
TP53 transcriptional activity [6]. MDM2 also has E3 
ubiquitin ligase activity that has been demonstrated to 
cause polyubiquitination of TP53, leading to proteasomal 
degradation [7]. MDM2 itself is a transcriptional TP53 
target, indicating the presence of a negative autoregulatory 
feedback loop between MDM2 and TP53 [8]. Aberrant 
MDM2 activation has been suggested as a possible 
mechanism by which neuroblastoma cells escape death. 
In a study of 41 primary tumors, 36.6% harbored either 
an MDM2 amplification or a mutational or epigenetic 
inactivation of CDKN2A, a negative regulator of MDM2 
[5]. MYCN amplification occurs in approximately 45% 
of primary high-risk neuroblastomas and is the strongest 
independent negative prognostic risk factor in patients 
[9]. MDM2 and TP53 are MYCN transcriptional targets 
[10, 11], and MDM2 is a translational regulator of MYCN 
via mRNA stabilization in the cytoplasm [12]. MDM2 
haploinsufficiency inhibits tumor formation in a MYCN-
driven neuroblastoma mouse model [13]. Despite the low 
mutation rate of TP53 in neuroblastoma, the TP53-MDM2 
axis appears to be deregulated in at least a subgroup of 
high-risk neuroblastomas, identifying it as an actionable 
target.
The possibility to reactivate TP53 signaling by 
modulating MDM2-TP53 activity drove design and 
development of several small molecule inhibitors over 
the last 13 years. Nutlin-3 was the first selective MDM2 
inhibitor shown to activate TP53 and downstream 
signaling in preclinical neuroblastoma models [14–17]. 
Several other chemical classes of MDM2 inhibitors have 
been developed, among which RG7112, RG7388, MI-
63, NDD0005 and MI-773 have been demonstrated to 
suppress neuroblastoma cell viability and proliferation in 
preclinical models [18–23]. None of these inhibitors has 
proceeded to clinical trials with neuroblastoma patients to 
date. Limited in vivo potency and poor bioavailability have 
prohibited translation of the initially designed molecules 
into clinical trials [24, 25]. Early clinical trials with 
MDM2 inhibitors in adult patients were also limited by 
toxicity [26]. Even though several MDM2 inhibitors have 
already been tested in preclinical models of neuroblastoma 
and MDM2 validated as a promising target, the need 
remains to identify, develop and preclinically assess 
novel MDM2 inhibitors with greater efficacy, improved 
bioavailability and fewer toxic side effects.
Despite aggressive multimodal treatment strategies, 
long-term survival remains below 50% in patients with 
high-risk neuroblastoma [27], and outcome for patients 
with relapsed neuroblastoma is almost always fatal 
[28, 29]. Molecular targeted therapies such as MDM2 
inhibitors are expected to improve patient outcome. DS-
3032b is a novel orally available, dispiropyrrolidine-
based compound that impairs MDM2 binding to the TP53 
transcriptional activation domain. To date, preclinical 
testing of DS-3032b has not been reported. Initial 
results emerging from a phase I trial (NCT02319369) 
treating adults with relapsed/refractory hematological 
malignancies have shown that DS-3032b has 
pharmacodynamic activity and shows evidence of clinical 
efficacy (reduction of blast cells in bone marrow following 
15 cycles in 15 of 26 patients) with acceptable clinical side 
effects that included myelosuppression, nephrological and 
gastrointestinal symptoms [30]. Two further phase I trials 
are currently evaluating DS-3032b as a single agent in 
adult patients with advanced solid tumors or lymphomas 
(NCT01877382) or with relapsed/refractory multiple 
myeloma (NCT02579824), but it is too early to draw any 
conclusions. Given the growing clinical experience with 
DS-3032b in adults, it is well poised to enter trials for 
pediatric patients with cancers against which preclinical 
efficacy can be demonstrated.
We preclinically evaluated the potential of DS-
3032b for high-risk neuroblastoma. Neuroblastoma 
cell lines and xenograft tumor models were used to test 
efficacy and characterize the mechanisms of DS-3032b 
action resulting in TP53-mediated induction of cell cycle 
arrest, apoptosis and senescence. Our aim is to provide 
preclinical data to support the incorporation of DS-3032b 
into trials applying combination treatment regimens that 
include molecular targeted inhibitors for patients with 
high-risk, primary refractory or relapsed neuroblastoma.
RESULTS
High-level MDM2 expression in neuroblastoma 
predicts poor patient survival
TP53 inactivation via mutation is known to occur in 
less than 2% of primary neuroblastomas [2–4], but TP53 
function can also be disrupted by deregulated MDM2 
expression. We reanalyzed microarray expression data 
from a cohort of 476 primary neuroblastomas [31] to 
assess correlations between MDM2 expression and patient 
prognosis. We used MDM2 expression in the tumors to 
segregate patients into the upper quartile and the lower three 
quartiles. Kaplan–Meier analysis showed that high-level 
MDM2 expression in tumors correlated with poor event-
free and overall survival (Figure 1A-1B). Within stage 4 
neuroblastoma, correlation between MDM2 expression and 
poor event-free and overall survival is present in MYCN 
non-amplified tumors, but not in MYCN amplified tumors 
(Supplementary Figure 1). Three known risk factors, the 
presence of a MYCN amplification in the tumor, patient age 
> 18 months at diagnosis and stage 4 disease according to 
the International Neuroblastoma Staging System (INSS), 
significantly correlated with elevated MDM2 expression in 
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tumors (Figure 1C-1E). These results indicate that elevated 
MDM2 expression in neuroblastomas is associated with 
more aggressive disease. For this reason, patients with high-
risk neuroblastoma may benefit from a therapy targeting 
TP53-MDM2 signaling.
DS-3032b inhibits neuroblastoma cell growth 
and migration, and induces cell cycle arrest, 
senescence and apoptosis in a functional TP53 
background
We assessed the effect of the novel small molecule 
MDM2 inhibitor, DS-3032b, on several hallmarks of 
cancer in a panel of six neuroblastoma cell lines with 
varying genetic backgrounds. Two cell lines (SK-
N-SH, SH-SY5Y) were included that lacked MYCN 
amplifications as controls for the diploid MYCN genetic 
background. The other four cell lines harbored MYCN 
amplifications. The selected neuroblastoma cell lines 
were also reported to harbor wildtype or mutant TP53. We 
validated the TP53 mutational status in all six cell lines 
by sequence analysis of the entire TP53 coding region 
(Figure 2A). Our analyses confirmed published reports, 
and showed that SK-N-SH, SH-SY5Y, IMR32, IMR5 and 
LAN5 cell lines harbor wildtype TP53, while the Kelly 
cell line harbors a 529C>T (P177T) missense mutation in 
TP53. Relative MDM2 expression was higher in the five 
neuroblastoma cell lines lacking TP53 mutations than 
in Kelly cells (Figure 2B). DS-3032b treatment reduced 
viability in the SK-N-SH, SH-SY5Y, IMR32, IMR5 and 
LAN5 cell lines in a dose- and time-dependent manner, 
while the only cell line harboring a TP53 mutation (Kelly) 
was remarkably less sensitive to DS-3032b treatment 
(Figure 2C-2E). We directly examined the effect of 
DS-3032b on proliferation using a bromodeoxyuridine 
(BrdU) enzyme-linked immunosorbent assay (ELISA) 
assay. DS-3032b treatment for 48 h also reduced BrdU 
incorporation in all cell lines except Kelly in a dose-
dependent manner (Figure 2F). The effect of DS-3032b 
treatment on cell migration was investigated using the 
Figure 1: Elevated MDM2 expression levels in tumors are associated with poor patient overall and event-free survival 
as well as more aggressive neuroblastomas.  (A-B) Tumors from a cohort of 476 primary tumors were classified into high- or low-
expressing groups according to whether MDM2 expression was greater or lower than the third quartile MDM2 expression. Kaplan–Meier 
analysis of overall and event-free patient survival. (C-E) Association of MDM2 expression with prognostic markers (MYCN status, age, 
INSS stage) in 649 primary tumors. ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001.
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scratch assay in all cell lines except LAN5, which does not 
adhere strongly to cell culture plastic making this assay 
technically infeasible. Scratch healing was reduced in all 
cell lines except Kelly by 24-hour treatment with 250 nM 
DS-3032b (Figure 2G). The novel MDM2 inhibitor, DS-
3032b, suppressed viability, proliferation and migratory 
capacity in neuroblastoma cell lines with functional TP53, 
regardless of the presence of MYCN amplifications.
DS-3032b antiproliferative activity should result 
from the reactivation of TP53 target gene transcriptional 
activation, since it prevents MDM2 binding to the 
TP53 transactivation domain. MDM2 inhibition has 
Figure 2: DS-3032b treatment selectively inhibits viability, proliferation and migration of neuroblastoma cells with 
wildtype TP53 independently of MYCN status.  (A) TP53 mutational status, MYCN status and IC50 of DS-3032b after 72 h 
exposure in neuroblastoma cell lines. (B) MDM2 expression was higher in neuroblastoma cells with wildtype TP53 in comparison to the 
TP53 mutant cell line Kelly. (C-E) Dose-response curves for neuroblastoma cell lines treated with DS-3032b for 24, 48 and 72 h. (F and 
G) Proliferation (measured by BrdU ELISA) and migration (measured by scratch assay) were reduced by treatment with DS-3032b in cell 
lines with wildtype TP53, whereas the TP53 mutant cell line Kelly remained unaffected. Data represent mean values and SD (n = 3 per 
group). * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001. # = scratch assay was technically unfeasible for LAN5 cells due to poor 
adherence to cell culture plastic.
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been shown to induce cell cycle arrest, senescence or 
apoptosis in neuroblastoma cells [15, 16, 22, 23]. To 
test this hypothesis for DS-3032b, we assessed the 
effect of DS-3032b on these TP53-dependent cellular 
responses. Flow cytometric analysis produced cell cycle 
distribution profiles following 48 h of treatment with 
125 and 250 nM. DS-3032b treatment of neuroblastoma 
cell lines with wildtype TP53 enriched the proportion 
of cells in G1 and diminished the proportion of cells in 
S in a dose-dependent manner (Figure 3A), indicating 
that DS-3032b induces arrest at the G1/S transition. 
DS-3032b treatment did not alter the cell cycle profiles 
in Kelly cells (Figure 3A), confirming that functional 
TP53 is necessary to arrest cells at the G1/S transition. 
We also measured a dose-dependent increase in cell 
senescence in all cell lines with wild-type TP53 using 
a quantitative reporter assay that colorimetrically 
measures senescence-associated beta-galactosidase 
(SA-β-gal) activity (Figure 3B). We investigated the 
impact of DS-3032b treatment on the expression of 
TP53 and its downstream targets, MDM2, CDKN1A 
and BAX, using western blotting. DS-3032b upregulated 
MDM2, CDKN1A and BAX expression only in cell 
lines harboring wildtype TP53 (Figure 3C). Treatment 
strongly increased TP53 expression in cell lines 
harboring wildtype TP53, and slightly increased TP53 
expression in Kelly cells (Figure 3C). The moderate 
TP53 accumulation in Kelly cells is compatible 
with an increased stabilization of TP53 caused by 
the release from MDM2-mediated degradation. DS-
3032b treatment induced apoptosis in all cell lines 
harboring wildtype TP53 in a dose-dependent manner 
Figure 3: DS-3032b treatment stabilizes TP53 and selectively induces expression of TP53 target genes in neuroblastoma 
cells with wildtype TP53 leading to G1 cell cycle arrest and senescence induction.  (A) DS-3032b treatment induced 
accumulation of cells with wildtype TP53 in G1 phase and a decrease of cells in S phase in a dose-dependent manner, but not in Kelly cells. 
(B) Senescence (measured by senescence-associated beta-galactosidase (SA-β-gal) activity assay) was induced by DS-3032b treatment in 
cell lines with wildtype TP53, whereas Kelly cells remained unaffected. (C) Activation of the TP53 signaling was shown by induction of 
MDM2, CDKN1A and BAX in neuroblastoma cells harboring wildtype TP53, in comparison to Kelly cells. Data represent mean values 
and SD (n = 3 per group). ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001.
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Figure 4: DS-3032b treatment selectively induces apoptosis in neuroblastoma cells with wildtype TP53.  (A) Fraction 
of early (annexin V positive, propidium iodide (PI) negative) and late apoptotic cells (annexin V and PI positive) was increased by DS-
3032b exposure in a dose-dependent manner in neuroblastoma cell lines harboring wildtype TP53, in contrast to the TP53 mutant cell line 
Kelly. (B) Exemplary dot-plots of the neuroblastoma cell lines Kelly and SH-SY5Y after DS-3032b treatment showing an induction of 
double-positive cells (annexin V and PI positive) in cells with wildtype TP53, but not in cells with mutated TP53. (C) DS-3032b exposure 
increased caspase 3 activity in neuroblastoma cell lines (SH-SY5Y and IMR5) and primary neuroblastoma cells (OHC-NB-1) that harbor 
wildtype TP53, in contrast to Kelly cells. Data represent mean values and SD (n = 3 per group). * = P < 0.05, ** = P < 0.01, *** = P < 0.001, 
**** = P < 0.0001.
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in experiments flow cytometrically detecting annexin V 
and propidium iodide (PI) staining (Figure 4A-4B) and 
caspase 3 activity (Figure 4C). To add further preclinical 
evidence for DS-3032b activity in neuroblastoma, 
we demonstrated that DS-3032b treatment induced 
apoptosis in primary neuroblastoma cells (OHC-NB-1) 
by measuring caspase 3 activity (Figure 4C). DS-3032b 
treatment did not influence apoptosis in the Kelly 
cell line. We used ectopic expression of a dominant-
negative TP53 mutant (dn-TP53) to evaluate whether 
the effects of DS-3032b in neuroblastoma cells are a 
direct consequence of wildtype TP53 activation. Stable, 
ectopic dn-TP53 expression severely attenuated the 
DS-3032b-mediated reduction in viability, induction 
of apoptosis and increase in endogenous TP53 levels 
in both SH-SY5Y and IMR5 cells (Figure 5A-5F). 
Expression of dn-TP53 also attenuated the increase 
in CDKN1A and BAX expression in SH-SY5Y and 
IMR5 cells treated with DS-3032b (Figure 5E-5F). 
Transfection with an empty vector as a negative control 
had no effect on the response of either SH-SY5Y and 
IMR5 cells to DS-3032b treatment (Figure 5A-5E). 
CRISPR-mediated MDM2 knockout was performed 
representatively in SH-SY5Y cells, and mimicked the 
effect of DS-3032b treatment by inhibiting cell viability 
(Figure 5G-5H). These data highlight the necessity of 
functional TP53 for DS-3032b activity and indicate 
that the antiproliferative activity is achieved through 
reactivating the TP53 signaling.
To further support our data on the broad activity 
of DS-3032b in neuroblastoma cells, we compared gene 
expression profiles after treatment of SH-SY5Y and IMR5 
cells with DS-3032b. Linear model testing identified 462 
genes that were significantly differentially expressed 
after treatment in both cell lines, with 91 genes being up-
regulated and 371 genes being down-regulated (Figure 
6A). Principal component analysis revealed that 60% of 
the variation in the expression data was accounted for by 
the cell line, demonstrating that SH-SY5Y and IMR5 have 
largely different gene expression profiles (Figure 6B). 
Treatment with DS-3032b induced pronounced changes 
in gene expression, accounting for 21% of the variation in 
the data (Figure 6B). Genes known to be transcriptionally 
activated by TP53 signaling, such as CDKN1A, were 
prominent among the up-regulated genes (Figure 6C), 
and gene set enrichment analysis confirmed that TP53 
signaling genes were significantly over-represented among 
the up-regulated genes (Figure 6D). Genes related to cell 
cycle progression, such as CCNA2 and CDC20, were 
among genes that were down-regulated by DS-3032b 
treatment (Figure 6C), and gene set enrichment analysis 
identified pathways related to cell cycle progression 
and DNA replication as being over-represented among 
down-regulated genes (Figure 6D). Our data support a 
reactivation of TP53 signaling by DS-3032b, regardless 
of the presence of a MYCN amplification.
DS-3032b delays tumor growth and improves 
survival in mice xenografted with neuroblastoma 
cells with functional TP53
We next assessed the efficacy of DS-3032b against 
SH-SY5Y xenograft tumors in nude mice as an animal 
model for the potential therapeutic benefit of DS-3032b. 
Mice with established xenograft tumors were treated 
for 30 consecutive days with an alternating schedule of 
4 days of daily treatment with oral gavages of 50 mg/
kg DS-3032b followed by 2 days without treatment. 
The treatment regimen was well tolerated and did not 
alter the physical status or behavior of the mice, induce 
weight loss or produce any other obvious signs of toxicity. 
Tumor growth was significantly suppressed by DS-
3032b treatment in comparison to vehicle control (Figure 
7A). Survival in the mouse cohort was significantly 
prolonged by DS-3032b treatment (Figure 7B). Mean 
tumor volumes were 640.1 ±80.6 mm3 in DS-3032b 
treated mice compared to 1571.9 ±276.0 mm3 in vehicle-
treated mice after 9 days of treatment (Figure 7C). DS-
3032b treatment activated TP53 signaling, as measured by 
TP53, CDKNA1 and BAX expression, in the xenograft 
tumor tissue similarly to the neuroblastoma cell lines 
grown in vitro (Figure 7D). Xenograft tumors from DS-
3032b treated mice also displayed a higher proportion of 
apoptotic cells and fewer proliferating cells as assessed 
by immunohistochemical detection of cleaved caspase 3 
and Ki-67 (MKI67), respectively (Figure 7E). DS-3032b 
treatment reduced neuroblastoma xenograft tumor growth 
by activating TP53 signaling in vivo.
DISCUSSION
A prerequisite for the successful use of MDM2 
inhibitors is a functional TP53 signaling machinery. 
As TP53 mutations occur in less than 2% of primary 
tumors [2–4], and only in 14% of relapse cases [5], 
neuroblastoma is expected to be especially susceptible 
to MDM2 inhibitors. Aberrant activation of the MDM2 
oncogene by gene amplification or inactivation of its 
inhibitory regulator CDKN2A occurs in 36.6% of primary 
neuroblastomas [5]. Here, we report that high-level 
MDM2 expression signals an unfavorable prognosis in 
a cohort of 476 primary neuroblastomas and correlates 
with clinical and molecular characteristics of unfavorable 
tumor biology. Within stage 4 neuroblastoma, correlation 
between MDM2 expression and unfavorable prognosis is 
limited to MYCN non-amplified tumors, indicating that 
the correlation is independent of MYCN status. Our results 
confirm a smaller retrospective study analyzing MDM2 
expression in 91 primary neuroblastomas, in which MDM2 
expression negatively correlated with event-free survival 
after three years [32]. However, a recent study analyzing 
MDM2 promotor SNP309 in 496 neuroblastoma patients, 
a single nucleotide polymorphism in the MDM2 promotor 
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Figure 5: Stable, ectopic expression of dominant-negative TP53 (dn-TP53) attenuates antiproliferative and pro-
apoptotic activity of DS-3032b, and CRISPR-mediated MDM2 knockout (KO) mimics DS-3032b treatment.  (A-D) 
Transfection with a plasmid encoding dn-TP53 rescued SH-SY5Y and IMR5 cells from DS-3032b mediated viability inhibition and 
apoptosis induction. (E-F) Basal level of TP53 in SH-SY5Y and IMR5 cells were increased by dn-TP53 transfection, but not by transfection 
with an empty control vector. DS-3032b mediated induction of CDKN1A and BAX expression was attenuated in dn-TP53 expressing SH-
SY5Y and IMR5 cells. (G-H) MDM2 knockout was performed using CRISPR vectors (GFP-tagged) and resulted in cell viability inhibition 
of SH-SY5Y cells. Fluorescence activated cell sorting for GFP-expressing cells was done 24 h after transfection. Cell viability (XTT assay) 
was measured 24, 48 and 72 h after sorting, and cells were harvested for western blotting 7 days after sorting. Data represent mean values 
and SD (n = 3 per group). ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001.
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that was shown to increase MDM2 expression [33], did 
not find an association between this polymorphism and 
overall or event-free survival [34]. There is clinical 
evidence that TP53 signaling contributes to tumor 
activity in neuroblastomas, but it is too early to draw any 
conclusions.
Here, we present the preclinical evaluation of the 
novel small-molecule MDM2 inhibitor, DS-3032b, for 
its value for treating patients with high-risk, refractory 
or relapsed neuroblastoma. Treatment with DS-3032b 
stabilized TP53 and selectively induced CDKNA1, 
BAX and MDM2 expression in neuroblastoma cells 
with wildtype TP53. TP53 accumulation and subsequent 
TP53 target gene activation have also been demonstrated 
in neuroblastoma cells with wildtype TP53 following 
treatment with other MDM2 inhibitors, including RG7112, 
RG7388, MI-63, NDD0005 and MI-773 [18–23]. Here, 
we performed expression profiling of neuroblastoma cells 
with and without DS-3032b treatment in order to further 
scrutinize functional mechanisms of DS-3032b. Gene set 
Figure 6: Microarray data confirm TP53 reactivation in neuroblastoma cells, regardless of the presence of a MYCN 
amplification.  SH-SY5Y and IMR5 cells were treated with 125 nM DS-3032b for 24 h, before harvested for gene expression analysis 
using an Affymetrix hugene2.0 chip. (A) Heatmap visualizes 462 differentially expressed genes after DS-3032b treatment by showing 
expression values according to the color coding on the bottom left. Colored bars below the heatmap indicate the sample groups. The three 
replicates of each sample group are shown next to each other. (B) Principal component (PC) analysis of the complete data set (24,100 
genes, 12 samples) illustrating variation in the expression data between IMR5 and SH-SY5Y cells (PC1), and changes in gene expression 
induced by treatment with DS-3032b (PC2). (C) Changes in expression of CDKN1A, BAX, MDM2, CCNA2, CDC20, BUB1 and ASPM 
after DS-3032b treatment. The y-axis is scaled to show the total range of expression values in the complete microarray data set. (D) Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways that were found to be over-represented among the differentially expressed genes.
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Figure 7: DS-3032b delays tumor growth and improves survival in mice xenografted with wildtype TP53 neuroblastoma 
cells.  (A) Tumor growth was significantly delayed in mice treated with DS-3032b (n = 7), compared to controls (n = 7). (B) Survival 
was significantly prolonged by DS-3032b treatment. (C) Tumor volume on day 9 of treatment was significantly reduced in mice treated 
with DS-3032b. (D) Expression analysis showed a strong induction of TP53 and a slight induction of CDKN1A and BAX in tumors from 
2 mice treated with 4 doses of DS-3032b over a course of 36 h. (E) Immunohistochemical analysis showed increased apoptosis (cleaved 
caspase 3) and decreased proliferation (MKI67) in a representative tumor from mice treated with 4 doses of DS-3032b over a course of 36 
h. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
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enrichment analysis using Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways revealed a significant 
induction of genes involved in TP53-dependent cell cycle 
arrest and apoptosis. Interestingly, we could not identify 
relevant off-target effects possibly due to high specificity 
of DS-3032b. DS-3032b effectively inhibited cell viability, 
proliferation and migration by inducing apoptosis, G1 
cell cycle arrest and senescence in the work we present 
here. All neuroblastoma cell lines with wildtype TP53 
responded to DS-3032b treatment, regardless of the 
presence of MYCN amplifications, indicating that this 
MDM2 inhibitor may benefit high-risk patients with 
neuroblastomas having several molecular backgrounds. 
Independence of MYCN status on in vitro potency may 
be a particular feature of DS-3032b among MDM2 
inhibitors. Nutlin-3 and MI-63, both MDM2 inhibitors, 
have more effectively suppressed proliferation of MYCN-
amplified neuroblastoma cells compared to cells lacking 
MYCN amplifications [35]. We characterized the strong 
pro-apoptotic activity induced by DS-3032b in flow 
cytometry experiments with neuroblastoma cells, and 
demonstrated that DS-3032b induces apoptosis in a 
primary neuroblastoma cell line. Functional outcome of 
DS-3032b treatment was primarily dependent on the TP53 
status of the cell line, as evidenced by the finding that 
stable, ectopic expression of dn-TP53 attenuated antitumor 
activity of DS-3032b in SH-SY5Y and IMR5 cells. The 
remaining antiproliferative and pro-apoptotic activity 
of DS-3032b in cells with dn-TP53 could be mediated 
by TP73, a TP53 homolog also negatively regulated 
by MDM2 [36]. Lau et al. have reported that Nutlin-3 
treatment results in TP73-dependent apoptosis [37]. DS-
3032b may inhibit TP73-MDM2 binding in an analogous 
manner. The novel MDM2 antagonist DS-3032b was 
shown to be effective in neuroblastoma cells with wildtype 
TP53 by reactivating TP53 signaling.
Although we show that DS-3032b has potent 
antitumor activity as a single agent, treatment using 
MDM2 antagonists as single agents is likely to spur 
development of resistance mechanisms [38] and be unwise 
for patients. Patients with high-risk neuroblastoma are 
currently treated with genotoxic chemotherapy and/or 
radiotherapy. Tumor cells respond to DNA damage induced 
by chemotherapy or radiotherapy by activating machinery 
that halts cell cycle progression and stimulates DNA 
repair, or if the damage is too great, inducing senescence 
or apoptosis [39]. Chen et al. have demonstrated that the 
MDM2 antagonist RG7388 works synergistically with 
chemotherapeutic agents used in neuroblastoma treatment 
(cisplatin, doxorubicin, topotecan, temozolomide and 
busulfan) to achieve a stronger apoptosis induction in 
neuroblastoma cells in vitro [19]. Integrating DS-3032b 
treatment in the high-risk treatment protocol may be 
able to release the brakes on this machinery and increase 
apoptosis in neuroblastoma cells induced by genotoxic 
chemotherapy and/or radiotherapy.
We demonstrate that DS-3032b inhibits 
proliferation and increases apoptosis in neuroblastoma 
xenografts in nude mice. Nutlin-3, RG7112 and 
RG7388 have also been demonstrated to have antitumor 
activity against neuroblastoma mouse models [15, 18, 
22]. To date, however, none of the MDM2 inhibitors 
has entered clinical treatment of patients with 
neuroblastoma. RG7112, the first small-molecule 
MDM2 antagonist in clinical testing, demonstrated 
significant gastrointestinal and hematopoietic side 
effects but only modest clinical activity in phase 
I clinical trials conducted in adult patients with 
liposarcoma or leukemia [40, 41]. No visible signs of 
toxicity were observed in mice treated with DS-3032b 
in the work presented here. Preliminary results from 
an ongoing phase 1 trial treating adult patients with 
relapsed or refractory acute myeloid leukemia or high-
risk myelodysplastic syndrome with DS-3032b as a 
single agent have demonstrated acceptable clinical side 
effects and efficacy, with reduction of bone marrow 
blasts by the end of one cycle in 57.7% of patients 
[30]. The indications from both our preclinical animal 
experiments and initial data from trials in adult patients 
supports the view that DS-3032b achieves MDM2 
inhibition with fewer toxic side effects, and is likely 
a promising MDM2 small molecule inhibitor for entry 
into pediatric patient trials for neuroblastoma.
Our preclinical data adds further evidence that 
targeted disruption of TP53-MDM2 binding results in 
potent antitumor activity in neuroblastoma cells. We 
provide the first preclinical feasibility study of the 
novel orally available MDM2 antagonist DS-3032b 
in neuroblastoma. Future preclinical studies with DS-
3032b will be needed to determine the optimal dosage 
and timing for combination with established chemo- 
and radiotherapy treatment schedules. The pleiotropic 
activities and low toxicity suggest DS-3032b as 
the best available candidate to inhibit MDM2 for 
integration into clinical treatment protocols for high-
risk neuroblastoma.
MATERIALS AND METHODS
Tumor expression re-analysis from existing data
MDM2 expression values were derived from 
existing whole-genome expression profiles from 649 
primary neuroblastoma samples [31], 173 samples lacked 
survival data and had to be omitted from the survival 
analysis. Kaplan–Meier analyses for the neuroblastoma 
cohort were performed online in the R2 platform (http://
r2.amc.nl) and the resulting survival curve and P values 
(log-rank test) were downloaded. Tumor samples were 
classified into high- or low-expressing groups according 
to whether MDM2 expression was greater or lower than 
the third quartile MDM2 expression.
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Cell culture
The human neuroblastoma cell lines Kelly, SK-N-SH, 
SH-SY5Y, IMR32, IMR5 and LAN5 were grown in RPMI 
1640 supplemented with 10% FCS, L-glutamine and 1% 
penicillin/streptomycin. All cell lines were authenticated 
by short tandem genotyping by the German Collection 
of Microorganisms and Cell cultures (Braunschweig, 
Germany) prior to experiments. TP53 mutational status of 
all cell lines was analyzed using Sanger sequencing and 
multiplex ligation-dependent probe amplification in the 
laboratories of Reinhard Schneppenheim at the University 
Hospital Hamburg, Germany. DS-3032b (Daiichi Sankyo) 
was dissolved in DMSO and stored as a 20 mM stock 
solution in small aliquots at -20°C. Cells were exposed 
to 0 – 2000 nM DS-3032b, prepared as serial dilutions in 
complete culture medium, for the period indicated. The 
final DMSO concentration was kept at or below 0.01%. 
For caspase 3 activity experiments, OHC-NB-1 (wildtype 
TP53) was used as a primary neuroblastoma cell line.
For rescue experiments, IMR5 and SH-SY5Y cells 
(wildtype TP53) were transfected with a pMSCVpuro 
plasmid encoding dn-TP53 mutant (donated by Martin Eilers) 
containing the Val135 TP53 mutation or the pMSCVpuro 
plasmid alone as a control using TurboFect (Thermo Fisher 
Scientific). Transduced cells were selected by addition of 
puromycin (0.5 μg/ml) to the medium for 7 days.
For CRISPR-mediated MDM2 knockout, 
guide RNA (gRNA) sequence was designed using 
the Zhang lab CRISPR design tool (http://crispr.mit.
edu) and the Broad Institute sgRNA designer (http://
www.broadinstitute.org/rnai/public/analysis-tools/
sgrna-design). Global MDM2 knockout was achieved 
by two gRNAs targeting exon 2 of MDM2 (sequence 
5’ -> 3’: GTGGTTACAGCACCATCAGT and 
AGCTTCGGAACAAGAGACCC). Upon selection 
of gRNA, oligonucleotides were ordered, annealed 
and ligated into BbsI-digested CRISPR vectors px458 
(pSpCas9(BB)-2A-GFP; donated by Feng Zhang 
(Addgene plasmid #48138)) and px459 (pSpCas9(BB)-
2A-Puro V2.0; donated by Feng Zhang (Addgene 
plasmid #62988)). Generated vectors were validated 
by sequencing and directly used for cell-transfection 
using the Gene Pulser Xcell™ Electroporation system 
(Bio-Rad Laboratories) applying the settings suggested 
for neuroblastoma cell lines (200 V, 20 ms, 1 pulse). 
Fluorescence activated cell sorting for green fluorescent 
protein (GFP)-expressing cells was done 24 h after 
electroporation. Cell viability was measured 24, 48 and 
72 h after sorting, and cells were harvested for western 
blot analysis 7 days after sorting.
Real-time quantitative reverse transcription-PCR
Total RNA was isolated from cells with use of 
the NucleoSpin kit (Machenery-Nagel) and cDNA 
synthesis was performed using the SuperScript III 
reverse transcription kit (Invitrogen, Thermo Fisher 
Scientific). MDM2 expression was monitored using real-
time polymerase chain reaction (PCR) using Assays on 
Demand (Applied Biosystems). Expression values were 
normalized to GAPDH (Applied Biosystems).
Western blot analysis
Cells treated with 0, 125 and 250 nM DS-3032b 
for 48 h were solubilized in lysis buffer containing 50 
mM Tris-HCl, 1% NP-40, 0.25% sodium deoxycholate, 
150 nM NaCl, and 1 mM EGTA. Total protein (30-
50 μg) was fractionated on 10–12% sodium dodecyl 
sulfate polyacrylamide gel, transferred to a nitrocellulose 
membrane (Bio-Rad Laboratories) or polyvinylidene 
difluoride membrane (Roche). The following primary 
antibodies were used: MDM2 (1:500, Santa Cruz 
Biotechnology), TP53 (1:500, Santa Cruz Biotechnology), 
CDKN1A (1:500, Santa Cruz Biotechnology), BAX 
(1:1000, Cell Signaling Technology) and Actin (1:7500, 
Sigma-Aldrich) as the loading control. Anti-rabbit 
horseradish peroxidase (HRP, 1:5000, GE Healthcare) 
and anti-mouse HRP (1:5000, GE Healthcare) were used 
as secondary antibodies. Proteins were visualized using 
enhanced chemiluminescence detection reagents (Thermo 
Fisher Scientific) and analyzed on a Fusion FX7 detection 
device (Peqlab, Erlangen, Germany).
Cell viability, proliferation and senescence 
analysis
Cells were seeded in triplicate onto 96-well plates, 
incubated for 24 h to permit adherence, then treated with 
0 - 2000 nM DS-3032b for 24, 48 or 72 h. Cell viability 
was determined using the 2,3-Bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay 
(Sigma-Aldrich) according to the manufacturer’s protocol. 
The IC50 was calculated using GraphPad Prism 6.0 
(GraphPad Software). Cell proliferation was determined 
using the BrdU ELISA assay (Roche) according to the 
manufacturer’s protocol. Senescence was measured using 
the fluorometric SA-β-gal activity assay (Cell Biolabs 
Inc.) according to the manufacturer’s protocol and 
corrected for cell viability (XTT assay).
Migration analysis
A modified scratch assay was used for analysis of 
cell migration [42]. To minimize cell proliferation, tumor 
cells were starved in 0.5% serum medium, cultured in 
12-well plates, and scratched with the fine end of 100 μl 
pipette tips (time 0). Plates were washed with phosphate 
buffered saline (PBS) to remove detached cells, and 
incubated with 0 and 250 nM DS-3032b for 24 h. The 
scratched area was photographed using 10x objective and 
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the open image area was calculated using the software 
TScratch [43].
Cell cycle and apoptosis analysis
Cells were seeded in triplicate in 6-well plates, 
incubated for 24 h to permit adherence, and treated with 
0, 125 and 250 nM DS-3032b for 48 h. Prior to cell cycle 
analysis, cells were washed with PBS, resuspended in 
450 μl PBS with 50 μg/ml propidium iodide (PI, Sigma-
Aldrich) and 100 μg/ml RNAse (Sigma-Aldrich), and 
incubated at room temperature for at least 10 min. Prior 
to apoptosis analysis, cells were resuspended in 100 μl 
binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM 
CaCl2) with 2.5 μl fluorescein isothiocyanite (FITC)-
conjugated antibodies against annexin V (BD Biosciences) 
and 4 μl PI (50ug/ml), and incubated at 4°C for 15 min. 
105 cells were analyzed on the LSRFortessa X-20 using 
FACSDiva™ software (BD Biosciences). Data were 
analyzed using FlowJo v10 (FlowJo).
Caspase 3 activity analysis
Cells were seeded in 100 mm plates, incubated for 
24 h to permit adherence, and then treated with 0, 125 and 
250 nM DS-3032b for 48 h. After cell lysis in Cell Lysis 
Buffer (BioVision), 50 μg protein were incubated with 
Ac-DEVD-AFC (Biomol) at 37°C for 1 h, and caspase 
3 activity was measured with a multi-well fluorescence 
plate reader.
Affymetrix microarray analysis
SH-SY5Y and IMR5 cells plated at 106 cells/well in 
6-well plates, then after 24 h for attachment, were treated 
in triplicate with control medium and medium containing 
125 nM DS-3032b for 24 h. Gene expression was assayed 
using the Affymetrix GeneChip Human Gene 2.0 ST Array. 
Microarray data were processed with R/Bioconductor 
version 3.3 using the Brainarray annotation for hugene2.0 
and the vsn normalization method [44]. Differentially 
expressed genes after treatment were derived using the 
limma package [45]. Linear model testing was applied to 
test whether the treatment effect was significantly different 
from 0. Test P values were corrected for multiple testing 
using the False Discovery Rate method. Genes with 
a corrected P value < 0.1 and an absolute fold-change 
greater than 2 were called significantly differentially 
expressed. A heatmap of differentially expressed genes 
was created using the gplots package. Euclidean distance 
and complete-linkage clustering were used to cluster 
genes (rows), samples (columns) were not clustered. The 
Bioconductor package clusterProfiler was used to identify 
KEGG pathways that were significantly often associated 
to genes in a given gene list. Pathways with a P value < 
0.0001 were called significantly over-represented.
Xenograft tumor experiments in nude mice
SH-SY5Y cells were cultured to 80% confluency, 
harvested and suspended in a 200 μl volume of 
PBS:Matrigel (BD Biosciences) for subcutaneous 
inoculation (2 × 107 cells per mouse, n =14 mice) into 
the right flank of 4-week-old female athymic NCr (nu/
nu) mice. Mice were randomly assigned to either DS-
3032b or vehicle control groups (n = 7 mice per group) 
after tumors reached 150–250 mm3 in size. DS-3032b or 
vehicle control was administered by oral gavage at a dose 
of 50 mg per kg body weight in 0.5% methylcellulose 
solution (400 cps, Sigma-Aldrich). The treatment was 
carried out for 30 consecutive days with an alternating 
schedule of 4 days of daily treatment followed by 2 
days without treatment. Tumor growth was monitored 
using a caliper, and tumor volume was calculated using 
the formula (breadth × length × height)/2. Mice were 
euthanized by cervical dislocation when tumor size 
exceeded 2000 mm3. To examine the effects of DS-
3032b treatment on reactivation of the TP53 signaling, 
nu/nu mice with established SH-SY5Y xenografts were 
treated orally with 4 doses of DS-3032b (100 mg per kg 
body weight) over a course of 36 h (doses were given 
at 0, 12, 24 and 36 h; n = 2). Mice were euthanized by 
cervical dislocation 4 h after the last dose. The tumor 
was removed, and half of each tissue was snap-frozen in 
liquid nitrogen then stored at -80°C, and the other half 
of tissue was formalin fixed and paraffin embedded. All 
animal experiments were performed in accordance with 
the Council of Europe guidelines for accommodation and 
care of laboratory animals and protocols were approved 
by the Institutional Ethical Commission for Animal 
Experimentation.
Xenograft tumor immunohistochemistry
Paraffin-embedded 5 μm sections of SH-SY5Y 
xenografts from mice that had been treated with 4 
oral doses of 100 mg/kg DS-3032b or vehicle control 
for 36 h were deparaffinized in xylene, followed by 
rehydration by transfer through a graded alcohol series. 
The following primary antibodies were used: MKI67 
(rabbit anti-human, 1:100, Cell Signaling Technology) 
and cleaved caspase 3 (rabbit anti-human, 1:100, Cell 
Signaling Technology). Sections were incubated with 
primary antibody at 4°C overnight. An Alexa594-
conjugated secondary antibody (donkey anti-rabbit, 
1:350, Invitrogen, Thermo Fisher Scientific) was applied 
for 45 min at room temperature. After counterstaining 
of the nucleus with 4’,6-diamidino-2-phenylindole 
(DAPI, 1:1000, Roche) the slides were mounted using 
Vectashield anti-fade mounting medium (Vector 
Laboratories). Images were recorded on a high-resolution 
fluorescence microscope (Zeiss Axiovert 200).
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Statistical analysis
GraphPad Prism 6.0 was used for graphical 
presentation, calculation of standard deviation and further 
statistical analysis. Statistical significance of differences 
between treatment groups was determined using a 
Student’s t test. For in vivo experiments Kaplan-Meier 
survival curves were applied and statistical analysis was 
performed using the log-rank test.
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